CPT: 82679
Print Share


  • E1

Special Instructions

Nonpregnant patients only.

Expected Turnaround Time

4 - 5 days

Related Documents

Specimen Requirements


Serum from a serum separator tube


0.6 mL

Minimum Volume

0.4 mL (Note: This volume does not allow for repeat testing.)


Gel-barrier serum separator tube; red top tubes (without gel barrier) should not be used

Storage Instructions

Room temperature

Stability Requirements



Room temperature

14 days


14 days


14 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Sample collected with any tube other than a gel barrier (serum separator) tube

Test Details


Evaluate postmenopausal vaginal bleeding due to peripheral conversion of androgenic steroids. Increased estrone levels may be associated with increased levels of circulating androgens and their subsequent peripheral conversion.


Enzyme immunoassay (EIA)

Reference Interval

See table.

Age (y)

Male (pg/mL)1,2

Female (pg/mL)1,2

Tanner Stage I



Tanner Stage II



Tanner Stage III



Tanner Stage IV



Tanner Stage V





Adult (Premenopausal): 27−231

Menstrual Cycle (1-10 days): 19−149

Menstrual Cycle (11-20 days): 32−176

Menstrual Cycle (21-30 days): 37−200

Adult (Postmenopausal): 0−125

Additional Information

Estrone (E1) is a steroid, a weak estrogen, and a minor female sex hormone.3,4 Estrone is one of three major endogenous estrogens, the others being estradiol and estriol.3,4 Like the other estrogens, estrone is synthesized from cholesterol and secreted mainly from the gonads, though they can also be formed from adrenal androgens in adipose tissue. Estrone is primarily derived from metabolism of androstenedione in peripheral tissues, especially adipose tissues. Individuals with obesity have increased conversion of androstenedione to estrone, leading to higher concentrations. Estrone can be converted into estradiol and serves mainly as a precursor or metabolic intermediate of estradiol. In addition, an increase in the ratio of estrone to estradiol may be useful in assessing menopause in women.


1. Tietz NW, ed. Clinical Guide to Laboratory Tests. 4th ed. Philadelphia, Pa: WB Saunders Co; 2006:378-379.
2. Estrone RIA DSL8700-FOC-02 [package insert]. Beckman Coulter/ImmunoTech; 2018.
3. Coelingh Bennink HJT. Are all estrogens the same? Maturitas. 2004 Apr 15;47(4):269-275.15063479
4. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005 Aug;8 Suppl 1:3-63.16112947


Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions ofestrogens. N Engl J Med. 2002 Jan 31;346(5):340-352.11821512
Kronenberg H, Williams HR. The physiology and pathology of the female reporductive axis. In: Williams Textbook of Endocrinology. 11th ed. Philadelphia, Pa: Saunders/Elsevier; 2008:541-614.
Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S116-24.11511861


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
004564 Estrone, Serum 2258-2 004564 Estrone, Serum pg/mL 2258-2

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at